Liquid Biopsy Market Report: Trends, Forecast, and Competitive Analysis

Publisher: Lucintel
Publication Date: May, 2020
Healthcare / Medical Devices
Pages: 150+
Delivery Format: PDF

Trends, opportunities, and forecast in liquid biopsy market to 2024 by product (assays kits, instruments, and services), circulating biomarker (circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other circulating biomarkers (include circulating RNA (ctRNA and cfRNA) and cell-free protein biomarkers)), clinical application (early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring orthopedics), application (oncology, lung cancer, breast cancer, colorectal cancer, prostate cancer, liver cancer, other cancers (bladder cancer, pancreatic cancer, brain and nervous system cancer, ovarian cancer and melanoma), non-cancer application), end use (reference laboratories, hospitals and physician laboratories, academic and research centers, and other end users), and region (North America, Europe, Asia-Pacific, and ROW).

Report Features
Table of Contents
Pricing
Methodology
Request Sample
Compare Offers
Make an Offer

The future of the liquid biopsy market looks promising with opportunities in the reference laboratories, hospitals and physician laboratories, and academic and research centers. The global liquid bio

psy market is expected to grow with a CAGR of 23% from 2019 to 2024. The major growth drivers for this market are increasing prevalence of cancer, increasing preference for noninvasive procedures, rising emphasis on personalized medicine, and availability of funding for liquid biopsy research and development.

A report of more than 150 pages is developed to help in your business decisions. Sample figures with some insights are shown below. To learn the scope of, benefits, companies researched and other details of liquid biopsy market report download the report brochure

Liquid Biopsy Market Share Analysis of Major Manufacturers

The study includes the liquid biopsy market size and forecast for the global liquid biopsy market through 2024, segmented by product, circulating biomarker, clinical application, application, end use, and region as follows:

By Product [$M shipment analysis for 2013 – 2024]:

Assays Kits
Instruments
Services

By Circulating Biomarker [$M shipment analysis for 2013 – 2024]:

Circulating Tumor Cells (CTCs)
Circulating Tumor DNA (ctDNA)
Cell-Free DNA (cfDNA)
Extracellular Vesicles (EVs)
Other Circulating Biomarkers

By Clinical Application [$M shipment analysis for 2013 – 2024]:

Early Cancer Screening
Therapy Selection
Treatment Monitoring
Recurrence Monitoring Orthopedics

By Application [$M shipment analysis for 2013 – 2024]:

Oncology
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Liver Cancer
Other Cancers
Non-Cancer Application

By End Use [$M shipment analysis for 2013 – 2024]:

Reference Laboratories
Hospitals and Physician Laboratories
Academic and Research Centers
Other End Users

By Region [$M shipment analysis for 2013 – 2024]:

North America
- United States
- Canada
- Mexico
Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
Asia Pacific
- China
- India
- Japan
ROW
- Brazil

Some of the liquid biopsy companies profiled in this report include Biocept, Qiagen, Roche Diagnostics, Bio-Rad Laboratories, Menarini-Silicon Biosystems, Trovagene, Guardant Health, Mdxhealth, Genomic Health, Raindance Technologies, Thermo Fisher Scientific, and Illumina.

Some of the features of this report:

Market size estimates:Global liquid biopsy market size estimation in terms of value ($M) shipment.
Trend and forecast analysis:Market trend (2013-2018) and forecast (2019-2024) by segments and region.
Segmentation analysis:Global market size by product, circulating biomaker, clinical application, application, end use, and region.
Regional analysis:Global liquid biopsy market breakdown by North America, Europe, Asia Pacific, and the Rest of the World.
Growth opportunities:Analysis on growth opportunities in different applications and regions for liquid biopsy in the global liquid biopsy market.
Strategic analysis:This includes M&A, new product development, and competitive landscape for, liquid biopsy in the global liquid biopsy market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

This report answers following 11 key questions:

Q.1. What are some of the most promising potential, high-growth opportunities for the global liquid biopsy market by product (assays kits, instruments, and services), circulating biomarker (circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other circulating biomarkers ( include circulating RNA (ctRNA and cfRNA) and cell-free protein biomarkers.)), clinical application (early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring orthopedics), application (oncology, lung cancer, breast cancer, colorectal cancer, prostate cancer, liver cancer, other cancers (bladder cancer, pancreatic cancer, brain and nervous system cancer, ovarian cancer and melanoma), non-cancer application), end use (reference laboratories, hospitals and physician laboratories, academic and research centers, and other end users), and region (North America, Europe, Asia-Pacific, and ROW)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which regions will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the drivers and challenges of the liquid biopsy market?
Q.5. What are the business risks and threats to the liquid biopsy market?
Q.6. What are emerging trends in this liquid biopsy market and the reasons behind them?
Q.7. What are some changing demands of customers in the liquid biopsy market?
Q.8. What are the new developments in the liquid biopsy market? Which companies are leading these developments?
Q.9. Who are the major players in this liquid biopsy market? What strategic initiatives are being implemented by key players for business growth?
Q.10. What are some of the competitive products and processes in this liquid biopsy area and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11. What M & A activities have taken place in the last 5 years in liquid biopsy market?

Offer Amount (Per user license)	Retail price (Per user license)
$ .00	$4,850

Liquid Biopsy Market Report: Trends, Forecast, and Competitive Analysis

The future of the liquid biopsy market looks promising with opportunities in the reference laboratories, hospitals and physician laboratories, and academic and research centers. The global liquid bio

Are you looking for a Consultant?

Customers Who Viewed This Item Also Viewed